that Daiichi willfully infringed a patent owned by Washington State-based Seagen that covers technology for delivering chemotherapy drugs to cancer cells.
Daiichi said in a statement that it disagreed with the verdict and was exploring its options, including potential post-trial motions and an appeal. It also said the U.S. Patent and Trademark Office granted its request to review the patent's validity on Thursday.Seagen said it was pleased with the verdict and would request additional royalties on future sales of Enhertu in the United States until the patent expires in 2024.
Cambridge, U.K.-based AstraZeneca, which co-developed Enhertu and markets it in the United States with Daiichi, did not immediately respond to a request for comment. The jury did not find it responsible for any of the $41.8 million award.drug to treat metastatic breast cancer. AstraZeneca reported that sales of Enhertu outside of Japan were worth $426 million last year.in the U.S.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WebMD - 🏆 709. / 51 Read more »